Formulation: A crystalline solid

Purity: ≥98%

Schedule: I

• 3,4-Methylenedioxymethylamphetamine
• NSC 168383

Formulation: A neat solid

Purity: ≥98%

Schedule: I

• 3,4-Methylenedioxymethylamphetamine
• NSC 168383

Formulation: A solution in methyl acetate

Purity: ≥98%

• N-methoxycarbonyl MDMA
• N-methoxycarbonyl-3,4-Methylenedioxymethamphetamine
• N-Moc-3,4-Methylenedioxymethamphetamine

Formulation: A crystalline solid

Purity: ≥98%

• 2,3-Methylenedioxymethylamphetamine

Formulation: A crystalline solid

Purity: ≥98%

• FLEA
• N-hydroxy-3,4-Methylenedioxymethamphetamine
• N-OH MDMA

Formulation: A crystalline solid

Purity: ≥98%

• 2-chloro-4,5-MDMA
• 6-chloro-3,4-MDMA
• 2-chloro-4,5-Methylenedioxymethamphetamine

Formulation: A crystalline solid

Purity: ≥98%

• 2-bromo-4,5-MDMA
• 6-bromo-3,4-MDMA
• 2-bromo-4,5-Methylenedioxymethamphetamine

Formulation: A 1 mg/ml solution in methanol

• 3,4-Methylenedioxymethylamphetamine
• NSC 168383

Formulation: A crystalline solid

Purity: ≥98%

• 3,4-Methylenedioxymethamphetamine methyl homolog

Formulation: A solution in acetonitrile

Purity: ≥98%

• t-BOC-3,4-MDMA
• N-t-Butoxycarbonyl-MDMA
• 3,4-MDMA t-butyl Carbamate
• 3,4-Methylenedioxymethamphetamine t-butyl Carbamate

Formulation: A crystalline solid

Purity: ≥98%

Schedule: I

• (R)-(−)-3,4-Methylenedioxymethylamphetamine

Formulation: A crystalline solid

Purity: ≥98%

Schedule: I

• (S)-(+)-3,4-Methylenedioxymethamphetamine

Formulation: A 1 mg/ml solution in methanol

• 3,4-Methylenedioxymethylamphetamine-d₅

Formulation: A crystalline solid

Purity: ≥99% deuterated forms (d₁-d₃)

Schedule: I

• 3,4-Methylenedioxymethylamphetamine-d₃

Formulation: A solid

Purity: ≥99% deuterated forms (d₁-d₅)

Schedule: I

• 3,4-Methylenedioxymethylamphetamine-d₅

Formulation: A 100 µg/ml solution in methanol

• 3,4-Methylenedioxymethylamphetamine-d₅

Formulation: A solid

Purity: ≥98%

• 5-methoxy MDMA
• 5-methoxy-3,4-Methylenedioxymethylamphetamine

Formulation: A crystalline solid

Purity: ≥98% (cis and trans isomers)

Schedule: Listed

• 3,4-MDP-2-P Methyl Glycidic Acid

Formulation: A crystalline solid

Purity: ≥98%

• 4-FMA

Formulation: A crystalline solid

Purity: ≥98%

Formulation: A crystalline solid

Purity: ≥98%

• 2-FMA

Formulation: A crystalline solid

Purity: ≥98%

• 3,4-Methylenedioxydimethylamphetamine

Formulation: A 50 mg/ml solution in ethanol

Purity: ≥98%

Schedule: Listed

• Allydioxybenzene methylene ether
• NSC 11831

Formulation: A crystalline solid

Purity: ≥98%

Formulation: A crystalline solid

Purity: ≥98%

• 3,4-EDO-N-methylamphetamine
• 3,4-Ethylenedioxy-N-methylamphetamine